Arkolith/Insider Trading/ICPT/Form 4

Pruzanski Mark

DirectorINTERCEPT PHARMACEUTICALS, INC. (ICPT) · full profile →Form 4 · filed Nov 13, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
1 non-derivative · 13 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 8, 2023Tender(U)619K$19.00$11.8M0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 8, 2023Disposed to issuer(D)5K——0
Nov 8, 2023Disposed to issuer(D)332——0
Nov 8, 2023Disposed to issuer(D)1K——0
Nov 8, 2023Disposed to issuer(D)18K——0
Nov 8, 2023Disposed to issuer(D)13K——0
Nov 8, 2023Disposed to issuer(D)32K——0
Nov 8, 2023Disposed to issuer(D)635——0
Nov 8, 2023Disposed to issuer(D)30K——0
Nov 8, 2023Disposed to issuer(D)1K——0
Nov 8, 2023Disposed to issuer(D)39K——0
Nov 8, 2023Disposed to issuer(D)207——0
Nov 8, 2023Disposed to issuer(D)45K——0
Nov 8, 2023Disposed to issuer(D)889——0

Transaction Codes

U
See SEC Form 4 code table
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-117094) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML